Accéder au contenu
Merck

2,3-diaminopyridine bradykinin B1 receptor antagonists.

Journal of medicinal chemistry (2004-12-14)
Scott D Kuduk, Christina Ng, Dong-Mei Feng, Jenny M-C Wai, Raymond S L Chang, Charles M Harrell, Kathy L Murphy, Richard W Ransom, Duane Reiss, Magnus Ivarsson, Glenn Mason, Susan Boyce, Cuyue Tang, Thomayant Prueksaritanont, Roger M Freidinger, Douglas J Pettibone, Mark G Bock
RÉSUMÉ

Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
2,3-Diaminopyridine, 95%